FDA Extends Nexplanon Use - Takeaways - MDSpire

FDA Extends Nexplanon Use

US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.

  • By

  • Kathryn Wighton

  • January 20, 2026

  • 3 min

Share

  • 1

    The FDA approved extending Nexplanon's use from three years to five years based on clinical trial data.

  • 2

    The approval was supported by a study involving 399 women, showing no pregnancies during years 4 and 5.

  • 3

    No new safety findings were reported, and adverse reactions were consistent with the initial three years of use.

  • 4

    A Risk Evaluation and Mitigation Strategy (REMS) will be implemented to ensure proper insertion and removal.

  • 5

    Nexplanon is effective for pregnancy prevention but does not protect against HIV or other sexually transmitted diseases.

Original Source(s)

FDA Extends Nexplanon Use

  • by Kathryn Wighton

  • January 20, 2026

Related Content

Correction: Objective interpretation of intrapartum cardiotocography images using attention-guided convolutional neural networks

Menstrual Fluid May Aid in Endometriosis Detection

Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.